Trial Search Results
The Use of Prophylactic Antibiotics In the Management of Dog Bites
This double blinded RCT will help to ascertain the usefulness of prophylactic antibiotics in the management of uncomplicated dog bites, utilizing currently best available antibiotics (Augmentin) and an important clinical outcome of infection.
By enrolling 100-150 patients in this pilot trial as part of a k-award the investigators plan to utilize the point estimates of infection, side effects and other important outcomes and incorporate these into a cost most to determine the most cost effective management of these wounds and to determine if further study is warranted based on the findings.
Stanford is currently not accepting patients for this trial.
Collaborator: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Drug: Augmentin
Phase 2/Phase 3
All patients including all children and English speaking/reading persons who present with a
full thickness dog bite to participating emergency departments will be considered.
Non-English speaking/reading subjects for whom we can provide translation for will also be
- allergy to penicillin or amoxicillin/clavulanic acid
- wounds presenting with an active infection (require antibiotics) or greater than 12
- patients with underlying fracture, joint or neurovascular injury, or multiple trauma
requiring specialty referral. Specifically any broken skin over a joint will need
treatment and be excluded from the study and randomization.
- patients on immunosuppressive agents, prolonged chronic steroid use (defined as
continuous use for > 14 days, 3 times a year) active HIV disease (determined by
treating physician on history) or splenectomized. (could skew one group and at risk
for overwhelming sepsis and death if infected)
- patients unwilling or unable to complete the required follow-up, and those unable to
provide a contact phone number
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study